Hubert Galinat

Hubert Galinat

Auto-generated profile, based on publicly available information

Hubert Galinat

Brest Univ Hosp, Hematol Lab, Blvd Tanguy Prigent, F-29200 Brest, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Autoimmunity
Verified
Journal Article
Closed access
AMAdrien Marziale
Adrien Marziale
EBEléonore Bettacchioli
Eléonore Bettacchioli
GPGael Picart
Gael Picart
SNSalma Nafai
Salma Nafai
HGHubert Galinat
Hubert Galinat
YRYves Renaudineau
Yves Renaudineau

1 September 2020 in Journal of Applied Physiology
Verified
Journal Article
Open access
PDF file
JLJacky Lautridou
Jacky Lautridou
EDEmmanuel Dugrenot
Emmanuel Dugrenot
AAAline Amérand
Aline Amérand
AGAnthony Guernec
Anthony Guernec
KPKarine Pichavant-Rafini
Karine Pichavant-Rafini
FGFrançois Guerrero
François Guerrero
Decompression sickness (DCS) is a complex and poorly understood systemic disease with wide inter-individual resistance variability. We selectively bred rats with a 3-fold greater resistance to DCS than standard ones. To investigate possible physiological mechanisms underlying the resistance to DCS, including sex-related differences in these mechanisms, 15 males and 15 females resistant to DCS were compared with aged-matched standard Wistar males (n=15) and females (n=15). None of these individuals had been previously exposed to hyperbaric treatment. Comparison of the allelic frequencies of SNPs showed a difference of one SNP located on the X chromosome. Compared with non-resistant rats, the neutrophil-to-lymphocyte ratio and the plasmatic activity of coagulation Factor X were significantly higher in DCS-resistant individuals regardless of their sex. The maximal relaxation elicited by sodium nitroprusside was lower in DCS-resistant individuals regardless of their sex. Males but not females resistant to DCS exhibited higher neutrophil and lymphocyte counts, higher prothrombin time whereas lower mitochondrial basal O2 consumption and citrate synthase activity. Principal Components Analysis showed that two principal components discriminate the DCS-resistant males but not females from the non-resistant ones. These components were loaded with aPTT, MLR, PT, FX, Fib, for PC1, and ARBC and ANC for PC2. In conclusion, the mechanisms which drive the resistance to DCS appear different between males and females; lower coagulation tendency and enhanced inflammatory response to decompression stress might be key for resistance in males. The involvement of these physiological adaptations in resistance to DCS must now be confirmed.

21 April 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
QAQuentin Allard
Quentin Allard
ZDZoubir Djerada
Zoubir Djerada
CPClaire Pouplard
Claire Pouplard
YRYohann Repesse
Yohann Repesse
DDDominique Desprez
Dominique Desprez
YCYoann Cazaubon
Yoann Cazaubon
We retrospectively analysed the data files of 171 adults and 87 children/adolescents with severe haemophilia, except for 14 patients (moderate; minor) (1), to develop a global population pharmacokinetic (PK) model for eight factors VIII (FVIII) that could estimate individual PK parameters for targeting the desired level of FVIII activity (FVIII:C); and (2) to compare half-life (HL) in patients switching from a standard half-life (SHL) to an extended half-life (EHL) and evaluate the relevance of the switch. One-stage clotting assay for the measurement of FVIII activity (FVIII:C, IU/mL) was used for population PK modelling. The software, Monolix version 2019R1, was used for non-linear mixed-effects modelling. A linear two-compartment model best described FVIII:C. The estimated PK parameters (between-subject variability) were: 2640 mL (23.2%) for volume of central compartment (V1), 339 mL (46.8%) for volume of peripheral compartment (V2), 135 mL/h for Q (fixed random effect), and 204 mL/h (34.9%) for clearance (Cl). Weight, age, and categorical covariate EHL were found to influence Cl and only weight for V1. This model can be used for all of the FVIII cited in the study. Moreover, we demonstrated, in accordance with previous studies, that Elocta had longer half-life (EHL) than SHL (mean ratio: 1.48) as compared to Advate, Factane, Kogenate, Novoeight, and Refacto.

18 May 2019 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
CHClaire Hoffmann
Claire Hoffmann
JAJean Amiral
Jean Amiral
SRSchéhérazade Rezig
Schéhérazade Rezig
HKHélène Kerspern
Hélène Kerspern
HJHélène Jantzem
Hélène Jantzem
HGHubert Galinat
Hubert Galinat

19 July 2023 in Biomedical Optics Express
Verified
Journal Article
Open access
LWLaura Wolff-Trombini
Laura Wolff-Trombini
ACAdrien Ceripa
Adrien Ceripa
JMJulien Moreau
Julien Moreau
HGHubert Galinat
Hubert Galinat
JCJames Chloe
James Chloe
JAJean-Marc Allain
Jean-Marc Allain
Hypercoagulability is a pathology that remains difficult to explain today in most cases. It is likely due to a modification of the conditions of polymerization of the fibrin, the main clot component. Using passive microrheology, we measured the mechanical properties of clots and correlated them under the same conditions with structural information obtained with confocal microscopy. We tested our approach with known alterations: an excess of fibrinogen and of coagulation Factor VIII. We observed simultaneously a rigidification and densification of the fibrin network, showing the potential of microrheology for hypercoagulability diagnosis.

6 January 2020 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
CMClélia Mornet
Clélia Mornet
DPDamien Luque Paz
Damien Luque Paz
ELEric Lippert
Eric Lippert
HGHubert Galinat
Hubert Galinat
FMFanny Mingant
Fanny Mingant